Insecticides (India)

Insecticides India reported a steady Q4 FY26 with 19% revenue growthCurrent reported value: 19% revenue growth. No comparable prior figure is available in the source record. in the quarter, though full-year revenue rose only 7% to ₹2,140 croreCurrent reported value: 7% to ₹2,140 crore. No comparable prior figure is available in the source record. and PAT dipped slightly to ₹139 croreCurrent reported value: ₹139 crore. No comparable prior figure is available in the source record. due to higher deferred tax. EBITDA margin improved to 10.6%Current reported value: 10.6%. No comparable prior figure is available in the source record. over three years, but Q4 margins were not disclosed. Growth was driven by premium products (up 24%Current 24%. Reported change: +24% YoY.) and B2C segment (73% of sales). Management remains cautiously optimistic for FY27, citing raw material inflation and sluggish May demand due to heatwaves, but expects improvement with monsoons. Key risks include prolonged geopolitical tensions keeping input costs elevated and potential weak monsoon impacting kharif season. The company is focusing on brand building through its ICS program and expanding its subsidiary Kyros as a parallel distribution channel.